There has been some further FDA action regarding Belviq which is related to the 2020 Belviq drug recall that was due to an increased risk of cancer. This further FDA action means there will be no Belviq generic drugs after the Belviq drug recall in 2020.
This February 26, 2021 Notice item, “Determination That BELVIQ (Lorcaserin Hydrochloride) Tablets, 10 Milligrams, and BELVIQ XR (Lorcaserin Hydrochloride) Extended-Release Tablets, 20 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness” appeared in the March 4, 2021 edition of the Federal Register.
From the Summary section of that 2021 Federal Register Notice:
The Food and Drug Administration (FDA or Agency) has determined that BELVIQ (lorcaserin hydrochloride) tablets, 10 milligrams (mg), and BELVIQ XR (lorcaserin hydrochloride) extended-release tablets, 20 mg, were withdrawn from sale for reasons of safety or effectiveness. The Agency will not accept or approve abbreviated new drug applications (ANDAs) for lorcaserin hydrochloride tablets, 10 mg and 20 mg.
According to that 2021 Federal Register Notice, this further FDA action regarding Belviq means:
[The FDA] will remove BELVIQ (lorcaserin hydrochloride) tablets, 10 mg, and BELVIQ XR (lorcaserin hydrochloride) extended-release tablets, 20 mg, from the list of drug products published in the Orange Book. FDA will not accept or approve ANDAs that refer to this drug product.
Going back to the February 2020 FDA Drug Safety Communication announcing the Belviq drug recall, “FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market”, these are some of the specific types of cancer associated with Belviq:
Pancreatic Cancer
Colorectal Cancer
Colon Cancer
Rectal Cancer
Lung Cancer
Our law firm is investigating possible Belviq lawsuits where patients have been diagnosed with cancer, including but not limited to the types listed above.
[Read article in full at original source]